Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.34 |
| ▸ | FDPS | P14324 | 4/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18559601 | 1.00 | OPRM1 (0.34) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL21160752 | 0.90 | OPRM1 (0.35) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL19852590 | 0.90 | OPRM1 (0.35) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL21161004 | 0.90 | OPRM1 (0.35) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL18559568 | 0.90 | OPRM1 (0.35) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL25813089 | 0.90 | OPRM1 (0.32) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL25014976 | 0.87 | OPRM1 (0.33) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL24087960 | 0.87 | FDPS (0.36) | FDPS | |
| SCHEMBL20214872 | 0.87 | FDPS (0.36) | FDPS | |
| SCHEMBL24453312 | 0.87 | OPRM1 (0.30) | OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723719-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723719-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | OPRM1 3571/4885OPRD1 3394/4885OPRK1 2579/4885 |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | OPRM1 3571/4885OPRD1 3394/4885OPRK1 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.